PROFILPELAJAR.COM

GSK484

GSK484
Identifiers
  • [(3S,4R)-3-amino-4-hydroxypiperidin-1-yl]-[2-[1-(cyclopropylmethyl)indol-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC27H31N5O3
Molar mass473.577 g·mol−1
3D model (JSmol)
  • CN1C2=C(C=C(C=C2OC)C(=O)N3CC[C@H]([C@H](C3)N)O)N=C1C4=CC5=CC=CC=C5N4CC6CC6
  • InChI=1S/C27H31N5O3/c1-30-25-20(11-18(13-24(25)35-2)27(34)31-10-9-23(33)19(28)15-31)29-26(30)22-12-17-5-3-4-6-21(17)32(22)14-16-7-8-16/h3-6,11-13,16,19,23,33H,7-10,14-15,28H2,1-2H3/t19-,23+/m0/s1
  • Key:BDYDINKSILYBOL-WMZHIEFXSA-N

GSK484 is an experimental drug which acts as a selective inhibitor of the enzyme peptidylarginine deiminase 4 (PAD4). It has antiinflammatory effects and has been researched for potential use in the treatment of various inflammatory conditions, primarily rheumatoid arthritis, but it has also been used to investigate the role of PAD4 in acute kidney injury, lung inflammation, heart muscle damage following heart attack, osteoporosis, diabetes, and some forms of cancer.[1][2][3][4][5][6][7][8][9][10][11]

See also

References

  1. ^ Koushik S, Joshi N, Nagaraju S, Mahmood S, Mudeenahally K, Padmavathy R, et al. (April 2017). "PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis". Expert Opinion on Therapeutic Targets. 21 (4): 433–447. doi:10.1080/14728222.2017.1294160. PMID 28281906.
  2. ^ Cedervall J, Dragomir A, Saupe F, Zhang Y, Ärnlöv J, Larsson E, et al. (2017). "Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice". Oncoimmunology. 6 (8) e1320009. doi:10.1080/2162402X.2017.1320009. PMC 5593702. PMID 28919990.
  3. ^ Mondal S, Thompson PR (March 2019). "Protein Arginine Deiminases (PADs): Biochemistry and Chemical Biology of Protein Citrullination". Accounts of Chemical Research. 52 (3): 818–832. doi:10.1021/acs.accounts.9b00024. PMC 6443095. PMID 30844238.
  4. ^ Du M, Yang W, Schmull S, Gu J, Xue S (January 2020). "Inhibition of peptidyl arginine deiminase-4 protects against myocardial infarction induced cardiac dysfunction". International Immunopharmacology. 78 106055. doi:10.1016/j.intimp.2019.106055. PMID 31816575.
  5. ^ Du M, Yang L, Gu J, Wu J, Ma Y, Wang T (2020). "Inhibition of Peptidyl Arginine Deiminase-4 Prevents Renal Ischemia-Reperfusion-Induced Remote Lung Injury". Mediators of Inflammation. 2020 1724206. doi:10.1155/2020/1724206. PMC 7787741. PMID 33456369.
  6. ^ Hu Z, Hua X, Mo X, Chang Y, Chen X, Xu Z, et al. (July 2023). "Inhibition of NETosis via PAD4 alleviated inflammation in giant cell myocarditis". iScience. 26 (7) 107162. Bibcode:2023iSci...26j7162H. doi:10.1016/j.isci.2023.107162. PMC 10391931. PMID 37534129.
  7. ^ Wang B, Su X, Zhang B, Pan S (September 2023). "GSK484, an inhibitor of peptidyl arginine deiminase 4, increases the radiosensitivity of colorectal cancer and inhibits neutrophil extracellular traps". The Journal of Gene Medicine. 25 (9) e3530. doi:10.1002/jgm.3530. PMID 37203323.
  8. ^ Salzmann M, Gibler P, Haider P, Brekalo M, Plasenzotti R, Filip T, et al. (January 2024). "Neutrophil extracellular traps induce persistent lung tissue damage via thromboinflammation without altering virus resolution in a mouse coronavirus model". Journal of Thrombosis and Haemostasis. 22 (1): 188–198. doi:10.1016/j.jtha.2023.09.014. PMID 37748582.
  9. ^ Guo Y, Zhou H, Wang Y, Gu Y (March 2025). "Activated NETosis of bone marrow neutrophils up-regulates macrophage osteoclastogenesis via cGAS-STING/AKT2 pathway to promote osteoporosis". Experimental Cell Research. 446 (2) 114477. doi:10.1016/j.yexcr.2025.114477. PMID 39988126.
  10. ^ Floyd JL, Prasad R, Dupont MD, Adu-Rutledge Y, Anshumali S, Paul S, et al. (April 2025). "Intestinal neutrophil extracellular traps promote gut barrier damage exacerbating endotoxaemia, systemic inflammation and progression of diabetic retinopathy in type 2 diabetes". Diabetologia. 68 (4): 866–889. doi:10.1007/s00125-024-06349-4. PMC 11950064. PMID 39875729.
  11. ^ Lu Z, Zhu L, Yi C, Su B, Wang R (December 2025). "C5a/C5aR regulates Th1/Th2 imbalance in sepsis-associated lung injury by promoting neutrophil activation to increase PAD4 expression". Annals of Medicine. 57 (1) 2447406. doi:10.1080/07853890.2024.2447406. PMC 11749016. PMID 39831526.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.